Preclinical CRO Market: Growth Factors & Competitive Analysis, 2027

Your avatar
The global Preclinical CRO Market size is expected to reach USD 7.8 billion by 2027, registering a CAGR of 8.3% over the forecast period, according to a new report by Grand View Research, Inc. The market is expected to show lucrative growth due to increasing R&D expenditure and rising outsourcing trend, which is expected to increase the demand for preclinical trials in the future. Whereas rise in number of complex drugs entering clinical trials and increasing R&D expenses are some of the factors responsible for the preclinical Contract Research Organization (CRO) growth. Increasing prices and changes in reimbursement policies are also anticipated to boost the in emerging countries such as India and China.
Increasing number of new entrants in market is anticipated to help the market to grow during the forecast period. Various companies are focusing on research and development of new drugs and therefore are outsourcing these activities to launch efficient CRO services in the market.
Request a free sample copy or view report summary: Preclinical CRO Market Report
Preclinical CRO Market Report Highlights
  • Toxicology testing held the largest share in the service segment in 2019 due to increasing trend of outsourcing, especially in emerging countries
  • Bioanalysis is expected to grow with the highest CAGR of 8.8% over the forecast period
  • North America dominates the market with the largest share of 47.5% in 2019 owing to advanced healthcare infrastructure in the region
  • The Asia Pacific region is projected to witness the fastest growth during the forecast period owing to government support in development of outsourcing hubs along with availability of skilled practitioners
  • Some of the key preclinical CRO market players are Envigo Corporation, MPI research, and Eurofins Scientific.

Keep discovering on Mamby:

If you liked this post, you may also be interested in...
Information Work with us Contact Terms and Conditions FAQs
© 2021, Mamby Investments